Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00385-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsenc=p2ANqtz--HZEsBHWVjztGCu8HwlXps9qG1Rc_FFULhyrWMs1NH2NSgKQWneAeslmqYE-INlxiS7sduHxZRRxrArqMHjEB5EXXLWA&_hsmi=356487988&utm_content=356303552&utm_source=hs_email